However, JP Morgan analysts maintain a positive outlook for several key players. Eli Lilly And Co. LLY, a top pick for the ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a ...

The opportunity for innovation in the local private health sector is enormous, especially in lower-income markets. Early ...

Shares of Merck & Co. Inc. MRK rose 1.20% to $99.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.04% to ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...